| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5614638 | Journal of Cardiology | 2017 | 7 Pages |
Abstract
The present trial demonstrated that liraglutide treatment after onset of STEMI was well-tolerated in Japanese patients with T2DM over 24 weeks, and provided the first evidence to support clinical application of liraglutide treatment even just after ACS in Japanese high-risk T2DM patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Masataka MD, Atsushi MD, PhD, Tomohiro MD, Koichi MD, PhD, FJCC, Tomohiro MD, PhD, FJCC, Shigeru MD, PhD, FJCC, Teruo MD, PhD, FJCC, Nobuhiko MD, Koichi MD, PhD, FJCC,